Current/JJ
Progress/NN
of/IN
Next/RB
Generation/NN
Battery/NN
of/IN
Toxicology/NN
Cellular/JJ
and/CC
Molecular/JJ
Toxicology/NN
,/,
and/CC
Toxicogenomics/NNS
./.
====================
The/DT
detection/NN
and/CC
the/DT
regulation/NN
of/IN
synthetic/JJ
chemicals/NNS
and/CC
the/DT
establishment/NN
of/IN
toxicity/NN
that/IN
may/MD
pose/VB
a/DT
genetic/JJ
hazard/NN
in/IN
our/PRP$
environment/NN
are/VBP
subjects/NNS
of/IN
great/JJ
concern/NN
because/IN
of/IN
its/PRP$
close/JJ
correlation/NN
between/IN
environmental/JJ
contamination/NN
and/CC
human/JJ
health/NN
./.
====================
Since/IN
the/DT
tens/NNS
of/IN
thousands/NNS
of/IN
man-made/NN
chemicals/NNS
that/DT
have/VBP
been/VBN
introduced/VBN
into/IN
the/DT
environment/NN
in/IN
the/DT
last/JJ
few/JJ
decades/NNS
must/MD
also/RB
be/VB
tested/VBN
for/IN
their/PRP$
damaging/NN
effect/NN
on/IN
DNA/NN
,/,
the/DT
agents/NNS
that/WDT
cause/VBP
this/DT
damage/NN
must/MD
be/VB
identified/VBN
./.
====================
Toxicology/NN
has/VBZ
been/VBN
defined/VBN
as/IN
the/DT
qualitative/JJ
and/CC
quantitative/JJ
study/NN
of/IN
the/DT
adverse/JJ
effects/NNS
of/IN
xenobiotics/NNS
on/IN
living/JJ
organisms/NNS
./.
====================
Moreover/RB
,/,
modern/NN
toxicology/NN
goes/VBZ
beyond/CC
the/DT
study/NN
of/IN
the/DT
adverse/JJ
effects/NNS
of/IN
exogenous/JJ
agents/NNS
to/TO
the/DT
study/NN
of/IN
cellular/JJ
and/CC
molecular/JJ
effects/NNS
of/IN
toxicants/NNS
using/VBG
molecular/JJ
biological/JJ
tools/NNS
./.
====================
Toxicology/NN
is/VBZ
a/DT
multidisciplinary/JJ
field/NN
,/,
and/CC
an/DT
important/JJ
science/NN
that/DT
impacts/VBZ
both/CC
environmental/JJ
health/NN
regulation/NN
and/CC
the/DT
development/NN
and/CC
practice/NN
of/IN
medicine/JJ
(/(
Klaassen/NNP
,/,
2001/CD
)/)
./.
====================
Classical/JJ
toxicological/JJ
tools/NNS
require/VBP
hundreds/VBZ
of/IN
animals/NNS
and/CC
provide/VBP
little/JJ
information/NN
with/IN
respect/NN
to/TO
mechanism/NN
(/(
s/NNS
)/)
./.
====================
For/IN
example/NN
,/,
descriptive/JJ
studies/NNS
in/IN
genetically/RB
inbred/VBN
animals/NNS
do/VBP
not/RB
explain/VB
genetic/JJ
and/CC
biological/JJ
differences/NNS
in/IN
the/DT
human/JJ
population/NN
that/WDT
influence/VBP
individual/JJ
====================
response/NN
to/TO
drugs/NNS
and/CC
environmental/JJ
xenobiotics/NNS
./.
====================
Recently/RB
,/,
several/JJ
new/JJ
methods/NNS
for/IN
the/DT
detection/NN
of/IN
genetic/JJ
damages/NNS
in/IN
vitro/FW
and/CC
in/IN
vivo/FW
were/VBD
introduced/VBN
according/VBG
to/TO
the/DT
rapid/JJ
progress/NN
in/IN
toxicology/NN
combined/JJ
with/IN
cellular/JJ
and/CC
molecular/JJ
biology/NN
(/(
Ryu/NNP
,/,
1999c/JJ
,/,
2002a/NN
,/,
b/LS
)/)
./.
====================
Among/IN
these/DT
methods/NNS
,/,
the/DT
single/JJ
cell/NN
gel/NN
electrophoresis/NN
(/(
comet/RB
assay/RB
)/)
which/WDT
can/MD
be/VB
detected/VBN
DNA/NN
damages/VBZ
in/IN
cell/NN
level/NN
(/(
Mckelvey-Martin/NNP
et/FW
al./FW
,/,
1993/CD
;/:
Singh/IN
et/FW
ai./IN
,/,
1988/CD
,/,
1991/CD
,/,
1994/CD
;/:
Ryu/NNP
et/FW
al./FW
,/,
1997/CD
;/:
Tice/RB
et/FW
al./FW
,/,
2000/CD
)/)
,/,
mouse/RB
lymphoma/NN
thymidine/NN
kinase/NN
gene/NN
assay/RB
(/(
Clive/JJ
et/FW
al./FW
,/,
1983/CD
;/:
Ryu/NNP
et/FW
al./FW
,/,
1999b/RB
)/)
,/,
FISH/NN
(/(
fluorescence/RB
in/IN
situ/FW
hybridization/NN
)/)
(/(
Hayashi/NNP
et/FW
al./FW
,/,
1994/CD
)/)
,/,
PRINS/NNP
(/(
primed/VBN
in/IN
situ/FW
hybridization/NN
)/)
(/(
Abbo/NNP
et/FW
al./FW
,/,
1993/CD
)/)
and/CC
transgenic/JJ
animal/JJ
and/CC
cell/NN
line/NN
model/NNP
as/IN
a/DT
parameter/JJ
of/IN
lac/JJ
I/RB
(/(
Big/NNP
Blue/NNP
)/)
(/(
Kohler/NNP
et/FW
al./FW
,/,
1991/CD
;/:
Ryu/NNP
et/FW
al./FW
,/,
1998a/RB
,/,
b/CC
,/,
1999a/RB
,/,
2000,2001/CD
c/NNP
)/)
or/CC
lac/RB
Z/NNP
(/(
Muta/NNP
Mouse/NNP
)/)
(/(
Suzuki/NNP
et/FW
al/RB
./.
====================
,1993/CD
)/)
gene/NN
mutation/NN
are/VBP
newly/RB
introduced/VBN
based/VBN
on/IN
cellular/JJ
and/CC
molecular/JJ
toxicological/JJ
approaches/NNS
./.
====================
Also/RB
,/,
in/IN
vivo/FW
supravital/JJ
micronucleus/NNS
assay/NN
with/IN
peripheral/JJ
reticulocytes/NNS
by/IN
using/VBG
acridine/JJ
orange/NN
fluorescent/JJ
staining/NN
(/(
Hayashi/NNP
et/FW
al./FW
,/,
1990/CD
;/:
Ryu/NNP
et/FW
al./FW
,/,
2001b/NN
)/)
was/VBD
introduced/VBN
instead/RB
of/IN
mouse/NN
bone/NN
marrow/NN
micronucleus/NNS
assay/NN
./.
====================
Moreover/RB
,/,
the/DT
rapid/JJ
progress/RB
in/IN
cellular/JJ
and/CC
molecular/JJ
biology/NN
,/,
like/IN
many/JJ
other/JJ
branches/NNS
of/IN
biomedical/JJ
research/NN
,/,
toxicology/NN
is/VBZ
now/RB
experiencing/VBG
a/DT
renaissance/RB
fueled/JJ
by/IN
the/DT
application/NN
of/IN
``/JJ
omic/JJ
''/NNP
technologies/NNS
to/TO
gain/VB
a/DT
better/RBR
understanding/NN
of/IN
the/DT
biological/JJ
basis/NN
of/IN
toxicology/NN
of/IN
drugs/NNS
and/CC
other/JJ
environmental/JJ
factors/NNS
(/(
Aederma/NNP
and/CC
McGregor/NNP
,/,
2002/CD
;/:
Hamadeh/NNP
and/CC
Afsari/NNP
,/,
2004/CD
)/)
./.
====================
In/IN
this/DT
review/NN
on/IN
current/JJ
toxicology/NN
,/,
at/IN
first/JJ
,/,
the/DT
rapid/JJ
progress/NN
of/IN
cellular/JJ
and/CC
molecular/JJ
toxicological/JJ
tools/NNS
,/,
and/CC
then/RB
concept/VBP
,/,
approaches/NNS
and/CC
applications/NNS
of/IN
toxicogenomics/NNS
will/MD
be/VB
described/VBN
./.
====================
Since/IN
the/DT
remarkable/JJ
progress/VBP
in/IN
cell/NN
biology/NN
and/CC
biochemistry/NN
,/,
the/DT
use/NN
of/IN
cell/NN
lines/NNS
,/,
enzymes/NNS
,/,
construction/NN
of/IN
genes/NNS
etc/JJ
became/VBD
more/RBR
easier/RBR
to/TO
handle/VB
in/IN
the/DT
laboratories/NNS
./.
====================
In/IN
this/DT
respect/NN
,/,
classical/JJ
toxicology/NN
moved/JJ
to/TO
cellular/JJ
and/CC
molecular/JJ
toxicology/NN
at/IN
present/JJ
,/,
and/CC
will/MD
move/VB
to/TO
toxicogenomics/NNS
(/(
Newton/JJ
etal./FW
,/,
2004/CD
)/)
in/IN
the/DT
near/JJ
future/JJ
./.
====================
For/IN
example/NN
,/,
genetic/JJ
toxicology/NN
has/VBZ
great/JJ
changes/NNS
in/IN
methodology/NN
and/CC
sensitivity/NN
./.
====================
Generally/RB
,/,
the/DT
carcinogenicity/NN
including/VBG
genotoxicity/NN
is/VBZ
one/CD
of/IN
the/DT
potential/JJ
toxicity/NN
that/IN
may/MD
consider/VB
for/IN
the/DT
human/JJ
health/NN
./.
====================
It/PRP
has/VBZ
been/VBN
widely/RB
assumed/VBN
that/IN
mutation/NN
represents/VBZ
at/IN
least/JJS
one/CD
step/NN
in/IN
carcinogenesis/NN
./.
====================
The/DT
evidence/NN
supporting/VBG
this/DT
idea/NN
is/VBZ
that/DT
the/DT
majority/NN
of/IN
mutagens/NNS
are/VBP
carcinogens/NNS
(/(
McCann/NNP
et/FW
al./FW
,/,
1975/CD
)/)
and/CC
,/,
for/IN
at/IN
least/JJS
some/DT
compounds/NNS
,/,
mutagenic/JJ
potency/NN
is/VBZ
closely/RB
correlated/VBD
====================
with/IN
carcinogenic/JJ
potency/NN
(/(
Meselson/NN
and/CC
Russel/NN
,/,
1977/CD
)/)
./.
====================
Moreover/RB
,/,
mutagensand/CC
certain/JJ
non-mutageniccarcinogens/NNS
have/VBP
also/RB
been/VBN
found/VBN
to/TO
induce/VB
chromosomal/JJ
rearrangement/NN
(/(
Zimmermann/NNP
,/,
1971/CD
)/)
which/WDT
may/MD
affect/VB
carcinogenesis/NN
by/IN
altering/VBG
gene/NN
expression/NN
,/,
perhaps/RB
by/IN
allowing/VBG
the/DT
activation/NN
or/CC
inactivation/NN
of/IN
cellular/JJ
cancer/NN
genes/NNS
(/(
Radman/JJ
etal./FW
,/,
1982/CD
)/)
./.
====================
Several/JJ
classical/JJ
genotoxicity/NN
assay/NN
systems/NNS
with/IN
rapidity/JJ
and/CC
reliability/NN
have/VBP
been/VBN
introduced/VBN
and/CC
practically/RB
applied/VBN
(/(
Ames/NNS
et/FW
al./FW
,/,
1973/CD
;/:
Maron/NNP
and/CC
Ames/NNS
,/,
1983/CD
;/:
Mersch-Sundermann/NNP
et/FW
al./FW
,/,
1991/CD
)/)
for/IN
predicting/VBG
the/DT
carcinogenicity/NN
of/IN
chemicals/NNS
and/CC
also/RB
been/VBN
introduced/VBN
to/TO
the/DT
evaluation/NN
of/IN
genotoxicity/NN
(/(
Ishidate/NNP
and/CC
Odashima/NNP
,/,
1977/CD
;/:
Radman/NNP
et/FW
a/DT
!/JJ
./.
,/,
1982/CD
;/:
Hayashi/NNP
et/FW
al./FW
,/,
1990/CD
,/,
1994/CD
;/:
Ryu/NNP
et/FW
al./FW
,/,
1993a/RB
,/,
b/LS
,/,
1997/CD
,/,
1999b/RB
)/)
and/CC
of/IN
antimutagenicity/JJ
(/(
Sato/NNP
etal./FW
,/,
1991/CD
;/:
Ryu/NNP
et/FW
al./FW
,/,
1993b/RB
,/,
2001b/NNP
)/)
./.
====================
Cytogenetic/JJ
studies/NNS
on/IN
mammalian/JJ
cells/NNS
in/IN
vivo/FW
(/(
Schmid/NNP
,/,
1975/CD
;/:
Hayashi/NNP
et/FW
al./FW
,/,
1990/CD
,/,
1994/CD
)/)
as/IN
well/RB
as/IN
in/IN
vitro/FW
(/(
Ishidate/NNP
and/CC
Odashima/FW
,/,
1977/CD
)/)
have/VBP
also/RB
been/VBN
widely/RB
used/VBN
as/IN
a/DT
screening/NN
method/NN
for/IN
DNA-attacking/JJ
substances/NNS
./.
====================
However/RB
,/,
these/DT
kinds/NNS
of/IN
toxicity/NN
evaluation/NN
tools/NNS
can/MD
not/RB
elucidate/VB
the/DT
mode/NN
and/or/CC
mechanism/NN
of/IN
actions/NNS
of/IN
chemicals/NNS
,/,
especially/RB
carcinogens/NNS
and/CC
mutagens/NNS
./.
====================
Moreover/RB
,/,
many/JJ
scientists/NNS
try/NN
to/TO
develope/VB
more/RBR
precise/JJ
,/,
convenient/JJ
and/CC
sensitive/JJ
techniques/NNS
for/IN
the/DT
detection/NN
of/IN
DNA/NN
damages/NNS
as/IN
an/DT
index/NN
of/IN
carcinogenicity/NN
./.
====================
Several/JJ
new/JJ
cellular/JJ
and/CC
molecular/JJ
genotoxicity/NN
assay/NN
systems/NNS
are/VBP
summarized/VBN
briefly/RB
as/IN
follows/VBZ
./.
====================
Single/JJ
Cell/NN
Gel/NN
Electrophoresis/NN
(/(
Comet/NN
)/)
assay/NN
:/:
Since/IN
Ostling/JJ
and/CC
Johanson/NN
(/(
1984/CD
)/)
introduced/VBD
microelectrophoretic/JJ
technique/NN
,/,
Singh/JJ
etal/JJ
./.
====================
(/(
1988/CD
)/)
have/VBP
modified/VBN
and/CC
improved/VBD
the/DT
microgel/NN
electrophoresis/NN
technique/NN
to/TO
evaluate/VB
DNA/NN
damage/NN
in/IN
single/JJ
cells/NNS
under/IN
alkaline/NN
conditions/NNS
./.
====================
The/DT
comet/JJ
assay/NN
is/VBZ
rapid/JJ
,/,
sensitive/JJ
,/,
visual/JJ
and/CC
simple/JJ
technique/NN
to/TO
quantify/VB
DNA/NN
strand/NN
breaks/NNS
in/IN
individual/JJ
cells/NNS
at/IN
least/JJS
3/CD
major/JJ
basic/JJ
protocols/NNS
(/(
Ostling/VBG
and/CC
Johanson/NN
,/,
1984/CD
;/:
Singh/IN
etal./FW
,/,
1988/CD
,/,
1991/CD
,/,
1994/CD
,/,
1995/CD
;/:
Olive/JJ
et/FW
al./FW
,/,
1993,1994/CD
)/)
./.
====================
If/IN
the/DT
agent/NN
can/MD
cause/VB
the/DT
strand/NN
breakage/NN
,/,
we/PRP
can/MD
see/VB
the/DT
extent/NN
of/IN
tail/NN
from/IN
the/DT
head/JJ
(/(
nucleus/NN
)/)
like/IN
comet/NN
with/IN
staining/NN
of/IN
fluorescent/JJ
dyes/NNS
such/JJ
as/IN
ethidium/NN
bromide/NN
,/,
acridine/VBP
orange/NN
and/CC
propidium/NN
iodide/NN
etc/NN
./.
====================
To/TO
harmonize/VB
comet/NN
assay/NN
,/,
International/NNP
Workshop/NNP
on/IN
Genotoxicity/NN
Test/JJS
Procedure/NN
(/(
IWGTP/NN
)/)
was/VBD
held/RB
at/IN
Washington/NN
D.C./NNP
on/IN
March/NN
,/,
1999/CD
by/IN
Environmental/JJ
Mutagen/NN
Society/NN
supported/VBD
with/IN
OECD/NN
./.
====================
Our/PRP$
laboratory/NN
(/(
Ryu/NNP
et/FW
al./FW
,/,
1997/CD
,/,
2001a/NN
,/,
2002c/JJ
)/)
also/RB
involved/VBN
in/IN
this/DT
harmonization/NN
and/CC
recommended/VBD
as/IN
OECD/NN
guideline/NN
with/IN
Tice/NN
etal/JJ
./.
====================
(/(
2000/CD
)/)
./.
====================
General/JJ
reviews/VBZ
on/IN
this/DT
technique/NN
have/VBP
been/VBN
published/VBN
by/IN
Tice/NN
et/FW
al/JJ
./.
====================
(/(
2000/CD
)/)
and/CC
Fairbairn/NN
etal/JJ
./.
====================
(/(
1995/CD
,/,
1996/CD
)/)
./.
====================
Mouse/NN
lymphoma/NN
thymidine/NN
kinase/NN
gene/NN
assay/NN
====================
(/(
MOLY/NN
)/)
:/:
MOLY/NN
with/IN
L5178Y/NN
tk+/-/CC
mouse/NN
lymphoma/NN
cells/NNS
described/VBN
by/IN
Clements/NNS
(/(
1994/CD
)/)
,/,
with/IN
minor/JJ
modification/NN
(/(
Clive/JJ
et/FW
a/DT
!/JJ
./.
,/,
1995/CD
,/,
Garriott/NNP
et/FW
al./FW
,/,
1995/CD
;/:
Oberly/RB
and/CC
Garriott/FW
,/,
1996/CD
;/:
Ryu/NNP
et/FW
al./FW
,/,
1999b/CD
)/)
./.
====================
The/DT
cytotoxicity/NN
of/IN
chemical/JJ
was/VBD
determined/VBN
by/IN
relative/JJ
survival/NN
(/(
RS/NN
)/)
after/IN
3/CD
hr/NN
treatment/NN
at/IN
concentrations/NNS
up/IN
to/TO
5,000/CD
ng/ml/NN
in/IN
the/DT
presence/NN
and/CC
absence/NN
of/IN
S-9/NN
mixture/NN
./.
====================
The/DT
highest/JJS
concentration/NN
chosen/NN
was/VBD
one/CD
with/IN
a/DT
10-20/CD
%/NN
RS/NN
./.
====================
Cultures/NNS
were/VBD
exposed/VBN
to/TO
the/DT
test/NN
chemical/JJ
for/IN
3/CD
hr/NN
,/,
then/RB
cultured/VBN
for/IN
2/CD
days/NNS
before/IN
plating/VBG
in/IN
96-well/JJ
microtiter/NN
plates/VBZ
at/IN
2000/CD
cells/well/JJ
with/IN
trifluorothymidine/NN
for/IN
mutant/JJ
selection/NN
and/CC
at/IN
1.6/CD
cells/well/JJ
for/IN
cell/NN
viability/NN
./.
====================
The/DT
number/NN
of/IN
wells/NNS
containing/VBG
colonies/NNS
was/VBD
counted/VBN
on/IN
day/NN
12/CD
after/IN
plating/VBG
,/,
and/CC
large/JJ
and/CC
small/JJ
colonies/NNS
were/VBD
scored/VBN
./.
====================
Mutation/NN
frequencies/NNS
were/VBD
analyzed/VBN
by/IN
the/DT
statistical/JJ
package/NN
,/,
Mutant/JJ
V2.31/NN
program/NN
(/(
Hazleton/NN
,/,
England/NN
)/)
in/IN
accordance/NN
with/IN
the/DT
UKEMS/NN
guidelines/NNS
./.
====================
Supravital/JJ
staining/NN
in/IN
vivo/FW
micronucleus/NNS
assay/NN
with/IN
peripheral/JJ
reticulocytes/NNS
:/:
The/DT
micronucleus/NNS
(/(
MN/NN
)/)
assay/NN
in/IN
vivo/FW
is/VBZ
a/DT
method/NN
devised/VBN
primarily/RB
for/IN
screening/VBG
chemicals/NNS
for/IN
chromosome-breaking/JJ
effects/NNS
./.
====================
In/IN
the/DT
monitoring/JJ
of/IN
chromosome/NN
breakage/NN
,/,
the/DT
test/NN
is/VBZ
at/IN
least/JJS
as/IN
sensitive/JJ
as/IN
the/DT
metaphase/NN
method/NN
;/:
in/IN
addition/NN
it/PRP
includes/VBZ
effects/NNS
on/IN
the/DT
spindle/NN
apparatus/NN
./.
====================
This/DT
MN/NN
assay/NN
using/VBG
peripheral/JJ
blood/NN
erythrocytes/NNS
was/VBD
introduced/VBN
by/IN
MacGregor/NN
et/FW
al./FW
,/,
(/(
1980/CD
)/)
and/CC
developed/VBD
by/IN
Hayashi/NN
et/FW
al/JJ
./.
====================
(/(
1990/CD
,/,
1994/CD
)/)
having/VBG
more/RBR
simple/JJ
and/CC
convenient/JJ
compared/VBN
to/TO
conventional/JJ
bone/NN
marrow/NN
assay/NN
by/IN
the/DT
introduction/NN
of/IN
supravital/JJ
staining/NN
with/IN
acridine/NN
orange/NN
(/(
Ryu/NNP
et/FW
al./FW
,/,
2001/CD
b/LS
)/)
./.
====================
The/DT
conventional/JJ
Giemsa/NN
staining/NN
method/NN
,/,
however/RB
,/,
has/VBZ
some/DT
disadvantages/NNS
because/IN
not/RB
only/RB
MNs/NNS
but/CC
also/RB
some/DT
cell/NN
inclusions/NNS
containing/VBG
RNA/NN
and/CC
other/JJ
acidic/JJ
materials/NNS
are/VBP
stained/VBN
dark/NN
blue/JJ
by/IN
Giemsa/NN
;/:
it/PRP
is/VBZ
occasionally/RB
difficult/JJ
to/TO
identify/VB
MNs/NNS
from/IN
these/DT
inclusions/NNS
./.
====================
Acridine/NN
orange/NN
metachromatic/JJ
fluorochrome/NN
discriminates/VBZ
between/IN
DNA/NN
and/CC
RNA/NN
by/IN
green/CD
and/CC
red/JJ
fluorescence/NN
,/,
respectively/RB
./.
====================
In/IN
vitro/FW
cytokinesis-block/NN
micronucleus/NNS
assay/NN
:/:
The/DT
micronucleus/NNS
assays/NNS
have/VBP
emerged/VBN
as/IN
one/CD
of/IN
the/DT
preferred/JJ
methods/NNS
for/IN
assessing/VBG
chromosome/NN
damage/NN
because/IN
they/PRP
enable/VBP
both/CC
chromosome/NN
loss/NN
and/CC
chromosome/NN
breakage/NN
to/TO
be/VB
measured/VBN
reliably/RB
(/(
Heddle/JJ
etal./FW
,/,
1983/CD
)/)
./.
====================
Because/IN
micronuclei/NNS
can/MD
only/RB
be/VB
expressed/VBN
in/IN
cells/NNS
that/WDT
complete/JJ
nuclear/JJ
division/NN
a/DT
special/JJ
method/NN
was/VBD
developed/VBN
that/IN
identifies/VBZ
such/JJ
cells/NNS
by/IN
their/PRP$
binucleate/NN
appearance/NN
when/WRB
blocked/VBN
from/IN
performing/VBG
cytokinesis/NN
by/IN
cytochalasin-B/JJ
,/,
a/DT
microfilament-assembly/RB
inhibitor/NN
./.
====================
This/DT
assay/NN
allows/VBZ
better/RBR
precision/NN
because/IN
the/DT
data/NNS
obtained/VBN
are/VBP
not/RB
confounded/VBN
by/IN
altered/JJ
cell/NN
division/NN
kinetics/NNS
caused/VBD
by/IN
cytotoxicity/NN
of/IN
agents/NNS
tested/VBN
or/CC
sub-optimal/JJ
cell/NN
culture/NN
conditions/NNS
(/(
Fenech/NN
etal./FW
,/,
1999/CD
)/)
./.
====================
Transgenic/JJ
Mutagenesis/NN
assay/NN
system/NN
:/:
The/DT
transgenic/JJ
====================
mutagenesis/NN
system/NN
is/VBZ
a/DT
useful/JJ
and/CC
powerful/JJ
tool/NN
to/TO
evaluate/VB
the/DT
genotoxicity/NN
,/,
and/CC
it/PRP
also/RB
provides/VBZ
a/DT
window/JJ
of/IN
carcinogenesis/NN
and/CC
mutagenesis/NN
mechanisms/NNS
of/IN
chemicals/NNS
based/VBN
on/IN
information/NN
such/JJ
as/IN
mutation/NN
pattern/NN
,/,
frequency/NN
,/,
and/CC
location/NN
in/IN
sequence/NN
context/NN
of/IN
the/DT
lac/NN
I/NN
target/NN
gene/NN
(/(
Gorelick/NNP
,/,
1995/CD
)/)
./.
====================
The/DT
lac/NN
I/NN
transgenic/JJ
Big/NN
Blue/NN
Rat2/NN
fibroblast/NN
cell/NN
line/NN
carries/VBZ
over/IN
40/CD
copies/NNS
of/IN
lambda/NN
shuttle/JJ
vector/NN
(/(
Dycaico/NN
et/FW
al./FW
,/,
1994/CD
)/)
containing/VBG
lac/NN
I/NN
gene/NN
as/IN
a/DT
target/NN
(/(
Heddle/JJ
and/CC
Tao/NN
,/,
1995/CD
;/:
Summers/NNS
et/FW
al./FW
,/,
1989/CD
)/)
./.
====================
The/DT
lac/NN
I/NN
gene/NN
,/,
as/IN
a/DT
mutational/JJ
target/NN
,/,
is/VBZ
very/RB
useful/JJ
for/IN
the/DT
study/NN
of/IN
the/DT
mutational/JJ
characteristics/NNS
of/IN
a/DT
carcinogen/NN
for/IN
several/JJ
reasons/NNS
./.
====================
First/RB
,/,
the/DT
relatively/RB
small/JJ
size/NN
(/(
1,080/CD
bp/NN
of/IN
coding/VBG
region/NN
)/)
of/IN
lac/NN
I/NN
gene/NN
facilitates/VBZ
sequence/NN
analysis/NN
./.
====================
Second/RB
,/,
the/DT
expression/NN
of/IN
repressor/NN
protein/NN
permits/VBZ
a/DT
rapid/JJ
colorimetric/JJ
assay/NN
to/TO
screen/VB
for/IN
mutations/NNS
./.
====================
The/DT
mutations/NNS
induced/VBD
in/IN
the/DT
lac/NN
I/NN
gene/NN
can/MD
easily/RB
be/VB
quantified/VBN
by/IN
mutant/JJ
frequency/NN
(/(
MF/NN
)/)
,/,
and/CC
the/DT
precise/JJ
mutation/NN
type/NN
and/CC
distribution/NN
can/MD
quickly/RB
be/VB
identified/VBN
by/IN
direct/JJ
sequencing/NN
./.
====================
Moreover/RB
,/,
considering/VBG
that/IN
mutations/NNS
in/IN
lac/JJ
I/NN
gene/NN
induced/VBD
by/IN
chemicals/NNS
reflect/VBP
the/DT
effects/NNS
of/IN
mutagens/NNS
on/IN
other/JJ
endogenous/JJ
genes/NNS
such/JJ
as/IN
proto­/RB
oncogenes/NNS
and/CC
tumor/NN
suppressor/NN
genes/NNS
,/,
and/CC
that/IN
mutations/NNS
occurred/VBD
in/IN
these/DT
genes/NNS
are/VBP
the/DT
most/JJS
common/JJ
events/NNS
in/IN
many/JJ
types/NNS
of/IN
human/JJ
cancer/NN
(/(
Kohler/NNP
et/FW
al./FW
,/,
1991/CD
;/:
Gossen/NNP
et/FW
al./FW
,/,
1989/CD
)/)
,/,
this/DT
assay/NN
may/MD
provide/VB
a/DT
powerful/JJ
tool/NN
to/TO
predict/VB
the/DT
mutation/NN
spectrum/NN
induced/VBD
in/IN
cancer-related/JJ
genes/NNS
more/RBR
accurately/RB
(/(
Ryu/NNP
et/FW
al./FW
,/,
1998a/RB
,/,
b/LS
,/,
1999a/RB
,/,
2000/CD
)/)
./.
====================
The/DT
recent/JJ
completion/NN
of/IN
the/DT
human/JJ
genome/NN
sequencing/NN
project/VB
and/CC
the/DT
push/JJ
to/TO
finish/VB
the/DT
mouse/NN
genome/NN
have/VBP
raised/VBN
the/DT
stakes/NNS
in/IN
science/NN
with/IN
predictions/NNS
of/IN
disease/NN
cures/NNS
,/,
more/RBR
effective/JJ
and/CC
safer/JJR
pharmaceuticals/NNS
,/,
and/CC
a/DT
greater/JJR
understanding/NN
of/IN
environmental/JJ
effects/NNS
on/IN
human/JJ
health/NN
./.
====================
The/DT
impact/NN
of/IN
human/JJ
genome/NN
projects/VBZ
on/IN
toxicological/JJ
research/NN
is/VBZ
high/JJ
,/,
heralding/VBG
the/DT
emerging/VBG
technologies/NNS
of/IN
toxicogenomics/NNS
,/,
proteomics/VBZ
,/,
and/CC
bioinformatics/NNS
(/(
Lovett/JJ
,/,
2000/CD
;/:
Pollack/RB
,/,
2000/CD
)/)
for/IN
the/DT
future/JJ
use/NN
of/IN
these/DT
technologies/NNS
and/CC
their/PRP$
impact/NN
on/IN
drug/NN
discovery/RB
,/,
safety/NN
evaluation/NN
,/,
elucidation/NN
of/IN
pathways/NNS
of/IN
toxicity/NN
,/,
and/CC
risk/NN
assessment/NN
./.
====================
The/DT
basis/NN
of/IN
toxicogenomics/NNS
is/VBZ
summarized/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
The/DT
NIEHS/NN
established/VBN
the/DT
National/JJ
Center/NN
for/IN
Toxicogenomics/NNS
(/(
NCT/NN
)/)
in/IN
September/NN
2000/CD
./.
====================
According/VBG
to/TO
the/DT
center/NN
's/POS
mission/NN
statement/JJ
,/,
its/PRP$
goal/NN
is/VBZ
``/CD
to/TO
use/VB
the/DT
methodologies/NNS
and/CC
information/NN
of/IN
genomics/NNS
science/NN
to/TO
significantly/RB
improve/VB
our/PRP$
understanding/NN
of/IN
basic/JJ
biological/JJ
responses/NNS
to/TO
environmental/JJ
stressors//JJ
toxicants/NNS
./.
''/CD
====================
Paul/NN
Gilman/JJ
,/,
who/WP
is/VBZ
an/DT
assistant/JJ
administrator/NN
for/IN
EPA/NN
,/,
states/NNS
that/DT
toxicogenomics/NNS
is/VBZ
a/DT
powerful/JJ
tool/NN
====================
with/IN
great/JJ
promise/VBP
for/IN
risk/NN
assessment/NN
(/(
Bergeson/NN
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
And/CC
also/RB
,/,
he/RB
stressed/JJ
that/DT
EPA/NN
encourages/VBZ
and/CC
supports/VBZ
continued/JJ
genomics/NNS
research/NN
as/IN
a/DT
powerful/JJ
tool/NN
for/IN
understanding/VBG
the/DT
molecular/JJ
basis/NN
of/IN
toxicity/NN
and/CC
developing/VBG
biomarkers/NNS
of/IN
exposure/NN
,/,
effects/NNS
,/,
and/CC
susceptibility/NN
./.
====================
He/RB
also/RB
mentioned/VBN
that/DT
genomics/VBZ
information/NN
is/VBZ
useful/JJ
in/IN
a/DT
weight-of-the-evidence/NN
approach/NN
for/IN
human/JJ
health/NN
and/CC
ecological/JJ
risk/NN
assessments/NNS
on/IN
a/DT
case-by-case/NN
basis/NN
at/IN
this/DT
time/NN
./.
====================
By/IN
combining/VBG
these/DT
new/JJ
``/NNP
omics/VBZ
''/RB
approaches/NNS
with/IN
classical/JJ
and/or/CC
conventional/JJ
toxicological/JJ
methods/NNS
,/,
it/PRP
is/VBZ
possible/JJ
to/TO
develope/DT
the/DT
experimental/JJ
models/NNS
and/CC
strategies/NNS
to/TO
evaluate/VB
1/LS
)/)
the/DT
diverse/JJ
structure/NN
and/CC
properties/NNS
of/IN
various/JJ
chemicals/NNS
;/:
2/LS
)/)
the/DT
relationship/NN
between/IN
the/DT
time/NN
of/IN
exposure/NN
,/,
dose/RB
,/,
and/CC
health/RB
outcomes/NNS
;/:
3/LS
)/)
the/DT
influence/RB
of/IN
genetics/NNS
and/CC
behavioral/JJ
factors/NNS
;/:
4/CD
)/)
interaction/NN
between/IN
mutiple/JJ
components/NNS
of/IN
biological/JJ
systems/NNS
in/IN
development/JJ
of/IN
toxic/JJ
responses/NNS
;/:
5/CD
)/)
intrinsic/JJ
biological/JJ
health/RB
responses/NNS
with/IN
extremely/RB
low/JJ
concentration/NN
for/IN
long/JJ
time/NN
exposure/NN
,/,
and/CC
6/CD
)/)
toxicological/JJ
responses/NNS
of/IN
compounds/NNS
at/IN
an/DT
early/JJ
stage/NN
of/IN
the/DT
drug/NN
discovery/RB
process/RB
and/CC
health/RB
risk/NN
assessment/JJ
./.
====================
What/IN
is/VBZ
Toxicogenomics/NNS
?/.
====================
:/:
Toxicogenomics/NNS
,/,
in/IN
a/DT
broader/RBR
sense/NN
,/,
is/VBZ
defined/VBN
as/IN
a/DT
study/NN
of/IN
the/DT
response/NN
of/IN
a/DT
genome/NN
to/TO
hazardous/JJ
substances/NNS
,/,
using/VBG
:/:
i/LS
)/)
Genomic-scale/JJ
mRNA/NN
expression/NN
(/(
transcriptomics/NNS
)/)
,/,
ii/LS
)/)
Cell/NNP
and/CC
tissue/NN
wide/JJ
protein/NN
expression/NN
(/(
proteomics/NNS
)/)
,/,
and/CC
iii/LS
)/)
Metabolite/JJ
profiling/VBG
(/(
metabon/lomics/NNS
)/)
in/IN
combination/NN
with/IN
bioinformatic/JJ
methods/NNS
and/CC
conventional/JJ
toxicology/NN
(/(
In/IN
a/DT
narrow/JJ
sense/NN
,/,
it/PRP
refers/VBZ
to/TO
the/DT
use/NN
of/IN
transcriptomics/NNS
)/)
./.
====================
In/IN
relation/NN
to/TO
chemical/JJ
hazard/risk/NN
assessment/NN
,/,
this/DT
emerging/VBG
science/NN
could/MD
provide/VB
tools/NNS
for/IN
improving/VBG
the/DT
understanding/NN
of/IN
mechanism/NN
of/IN
toxicity/NN
,/,
identification/NN
of/IN
biomarkers/NNS
for/IN
prediction/NN
of/IN
toxicity/NN
and/CC
exposure/NN
,/,
and/CC
possibly/RB
alternative/JJ
methods/NNS
for/IN
chemical/JJ
screening/NN
,/,
hazard/RB
and/CC
toxicity/NN
identification/NN
,/,
characterization/NN
,/,
and/CC
classification/NN
./.
====================
Approaches/NNS
and/CC
Application/NN
of/IN
Toxicogenomics/NNS
:/:
The/DT
utilization/NN
of/IN
these/DT
new/JJ
technologies/NNS
along/IN
with/IN
more/RBR
established/JJ
genetic/JJ
approaches/NNS
such/JJ
as/IN
quantitative/JJ
real/JJ
time/NN
polymerase/NN
chain/NN
reaction/NN
(/(
QRT-PCR/NN
)/)
,/,
and/CC
the/DT
use/NN
of/IN
genetically/RB
altered/JJ
animalswill/DT
dramatically/RB
move/VBP
the/DT
field/NN
of/IN
toxicology/NN
forward/IN
./.
====================
As/IN
you/RB
know/VBP
well/RB
,/,
the/DT
recent/JJ
remarkable/JJ
advances/NNS
in/IN
genomics/NNS
,/,
proteomics/VBZ
,/,
and/CC
metabon/lomics/NNS
,/,
the/DT
interactions/NNS
between/IN
multiple/JJ
genes/NNS
,/,
proteins/NNS
,/,
and/CC
pathways/NNS
can/MD
now/RB
be/VB
investigated/VBN
with/IN
more/RBR
easy/RB
and/CC
time-saving/JJ
ways/NNS
(/(
Irwin/NNP
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
cDNA/NN
and/CC
oligonucleotide/NN
microarrays/NNS
and/CC
high-throughput/JJ
2-D/JJ
electrophoresis/NN
systems/NNS
have/VBP
quickly/RB
emerged/VBN
as/IN
the/DT
premier/NN
tools/NNS
to/TO
enable/VB
genomewide/NN
analysis/NN
of/IN
gene/NN
expression/NN
at/IN
the/DT
RNA/NN
and/CC
protein/NN
level/NN
./.
====================
These/DT
new/JJ
technologies/NNS
are/VBP
heavily/RB
influencing/VBG
drug/NN
discovery/NN
and/CC
preclinical/JJ
safety/NN
in/IN
the/DT
biotechnology/NN
and/CC
pharmaceutical/JJ
industry/NN
(/(
Freeman/JJ
,/,
2000/CD
,/,
2004/CD
)/)
./.
====================
Toxicologists/NNS
are/VBP
also/RB
promoting/VBG
genomic/JJ
expression/NN
technologies/VBZ
as/IN
a/DT
superior/JJ
alternative/JJ
to/TO
traditional/JJ
rodent/JJ
bioassays/NNS
to/TO
identify/VB
and/CC
assess/VB
the/DT
safety/NN
of/IN
chemicals/NNS
and/CC
drug/NN
candidates/NNS
for/IN
human/JJ
safety/NN
(/(
Afshari/NNP
et/FW
al./FW
,/,
1999/CD
;/:
Nuwaysiref/JJ
al./FW
,/,
1999/CD
;/:
Pennie/NNP
et/FW
al./FW
,/,
2000/CD
,/,
2002/CD
;/:
Ryu/NNP
et/FW
al./FW
,/,
2002d/JJ
)/)
./.
====================
It/PRP
is/VBZ
expected/VBN
that/DT
gene/NN
expression/NN
profiling/VBG
will/MD
identify/VB
mechanisms/NNS
of/IN
action/NN
that/IN
underlie/VBP
the/DT
potential/JJ
toxicity/NN
of/IN
chemicals/NNS
and/CC
drug/NN
candidates/NNS
./.
====================
Ultimately/RB
,/,
toxicogenomics/NNS
(/(
the/DT
integration/NN
of/IN
genomics/NNS
,/,
bioinformatics/NNS
,/,
and/CC
toxicology/NN
)/)
is/VBZ
expected/VBN
to/TO
accelerate/VB
drug/NN
development/NN
(/(
Suter/NN
,/,
2004/CD
;/:
Yang/NNP
et/FW
al./FW
,/,
2004/CD
)/)
,/,
and/CC
aid/VB
environment/NN
ecological/JJ
(/(
Neumann/NN
and/CC
Galvez/NN
,/,
2002/CD
)/)
and/CC
health/NN
risk/NN
assessment/NN
./.
====================
In/IN
the/DT
laboratory/JJ
,/,
these/DT
are/VBP
some/DT
examples/NNS
of/IN
questions/NNS
that/DT
researchers/NNS
will/MD
be/VB
able/JJ
to/TO
address/VB
by/IN
toxicogenomics/NNS
as/IN
follows/VBZ
;/:
Which/WDT
genes/NNS
are/VBP
regulated/VBN
upwards/IN
or/CC
downwards/IN
(/(
apoptosis/NN
,/,
cellular/JJ
proliferation/NN
,/,
metabolism/NN
,/,
communication/NN
and/CC
cell/NN
adhesion/NN
,/,
etc/JJ
./.
)/)
====================
following/VBG
an/DT
exposure/NN
to/TO
mercury/NN
,/,
PCBs/NNS
or/CC
triazines/NNS
pesticides/NNS
?/.
====================
Is/VBZ
the/DT
response/NN
similar/JJ
in/IN
the/DT
liver/NN
,/,
lung/NN
,/,
testes/VBZ
,/,
ovaries/VBZ
and/CC
brain/NN
?/.
====================
Are/RB
the/DT
responses/NNS
of/IN
animal/NN
and/CC
cell/NN
models/NNS
comparable/JJ
to/TO
humans/NNS
?/.
====================
The/DT
network/NN
is/VBZ
also/RB
particularly/RB
interested/JJ
in/IN
the/DT
genetic/JJ
factors/NNS
responsible/JJ
for/IN
environmental/JJ
contaminant-induced/JJ
breast/NN
cancers/NNS
,/,
unfavorable/JJ
pregnancy/NN
outcomes/NNS
,/,
and/CC
children/NN
’/CD
s/NNS
health/NN
./.
====================
The/DT
approaches/NNS
in/IN
the/DT
commercial/JJ
basis/NN
,/,
one/CD
of/IN
examples/NNS
,/,
TNO/NN
pharma/NN
(/(
2004/CD
)/)
has/VBZ
taken/VBN
up/IN
the/DT
challenge/NN
of/IN
toxicogenomics/NNS
./.
====================
A/DT
research/NN
program/NN
is/VBZ
initiated/VBN
with/IN
the/DT
following/VBG
features/NNS
;/:
====================
Embedding/VBG
in/IN
``/NN
classical/JJ
''/NN
toxicology/NN
:/:
comparison/NN
of/IN
multiple/JJ
gene/NN
expression/NN
and/CC
proteome/VBP
changes/NNS
induced/VBN
in/IN
vivo/FW
as/IN
a/DT
function/NN
of/IN
time/NN
and/CC
dose/NN
level/NN
./.
====================
Use/NN
of/IN
in/FW
vitro/FW
systems/NNS
to/TO
underscore/VB
in/IN
vivo/FW
findings/NNS
====================
(/(
but/CC
not/RB
the/DT
other/JJ
way/NN
around/IN
!/CD
)/)
./.
====================
Integrated/JJ
genomics/NNS
and/CC
proteomics/NNS
analysis/NN
of/IN
====================
target/NN
organs/NNS
./.
====================
Incorporation/NN
of/IN
kinetics/NNS
and/CC
metabolism/NN
in/IN
target/NN
====================
organ/NN
toxicity/NN
assessment/NN
./.
====================
Evaluation/NN
of/IN
possible/JJ
polymorphisms/NNS
in/IN
the/DT
mechanism/NN
of/IN
toxicity/NN
,/,
and/CC
the/DT
consequences/NNS
for/IN
extrapolation/NN
to/TO
the/DT
human/JJ
situation/NN
./.
====================
Combination/NN
of/IN
tissue/NN
microdissection/NN
and/CC
gene/NN
expression/NN
analysis/NN
in/IN
order/NN
to/TO
relate/VB
pathology/NN
and/CC
genomics/NNS
./.
====================
Comparison/NN
of/IN
gene/NN
expression/NN
changes/NNS
to/TO
a/DT
toxicogenomics/NNS
database/NN
to/TO
allow/VB
for/IN
classification/NN
of/IN
the/DT
effects/NNS
./.
====================
A/DT
proprietary/JJ
pathway/NN
related/JJ
bioinformatics/NNS
system/NN
====================
aiding/VBG
the/DT
toxicologist/NN
in/IN
understanding/VBG
the/DT
data/NNS
./.
====================
Complex/NN
data/NNS
analysis/NN
based/VBN
on/IN
pattern/NN
recognition/NN
====================
and/CC
proprietary/JJ
principle/NN
component/NN
analysis/NN
./.
====================
First/RB
grade/NN
technology/NN
(/(
``/CD
home-made/NN
''/CD
high/JJ
density/NN
DNA/NN
arrays/NNS
,/,
2D-proteomics/NNS
with/IN
MALDI-TOF/NN
and/CC
nanospray/NN
MS/NN
)/)
./.
====================
Advantages/NNS
and/CC
limitations/NNS
:/:
There/EX
are/VBP
both/CC
advantages/NNS
and/CC
limitations/NNS
to/TO
the/DT
use/NN
of/IN
gene/NN
microarray/NN
and/CC
proteomics/NNS
technologies/NNS
in/IN
toxicological/JJ
screening/NN
./.
====================
The/DT
main/JJ
advantage/NN
is/VBZ
a/DT
global/JJ
approach/NN
to/TO
understanding/VBG
the/DT
complex/NN
mechanisms/NNS
involved/VBN
in/IN
toxicology/NN
./.
====================
Gene/NN
microarrays/NNS
have/VBP
been/VBN
costly/RB
and/CC
limited/JJ
in/IN
availability/NN
,/,
but/CC
the/DT
past/NN
year/NN
has/VBZ
shown/VBN
a/DT
commitment/NN
by/IN
the/DT
scientific/JJ
community/NN
to/TO
the/DT
general/JJ
use/NN
and/CC
availability/NN
of/IN
gene/NN
microarrays/NNS
./.
====================
Consequently/RB
,/,
cost/JJ
has/VBZ
been/VBN
reduced/VBN
by/IN
increased/VBN
supply/RB
and/CC
demand/CC
./.
====================
Furthermore/RB
,/,
the/DT
availability/NN
and/CC
cost/JJ
is/VBZ
substantially/RB
improving/VBG
with/IN
many/JJ
universities/NNS
and/CC
research/NN
centers/NNS
establishing/VBG
genomic/JJ
and/CC
proteomic/JJ
facilities/NNS
./.
====================
Also/RB
recent/JJ
experiments/NNS
applied/VBD
to/TO
cancer/NN
genetics/NNS
have/VBP
demonstrated/VBN
the/DT
potential/JJ
of/IN
gene/NN
expression/NN
profiling/VBG
to/TO
accurately/RB
classify/VBP
disease/NN
phenotypes/NNS
(/(
Alizadeh/RB
et/FW
al./FW
,/,
2000/CD
;/:
Bittner/NNP
et/FW
al./FW
,/,
2000/CD
)/)
,/,
thus/RB
lending/VBG
hope/NN
that/DT
expression/NN
profiling/VBG
may/MD
classify/VB
and/CC
thus/RB
predict/VBP
phenotypes/NNS
of/IN
toxicity/NN
./.
====================
Despite/IN
these/DT
expectations/NNS
,/,
it/PRP
is/VBZ
still/RB
uncertain/JJ
how/WRB
gene/NN
expression/NN
profiling/VBG
experiments/NNS
will/MD
ultimately/RB
contribute/VBP
to/TO
our/PRP$
understanding/NN
of/IN
toxicity/NN
and/CC
allow/VBP
us/PRP
to/TO
realize/VB
the/DT
full/JJ
potential/JJ
of/IN
this/DT
new/JJ
technology/NN
./.
====================
Pennie/NN
et/FW
al/JJ
./.
====================
(/(
2000/CD
,/,
2002/CD
,/,
2004/CD
)/)
have/VBP
also/RB
discussed/VBN
the/DT
possibilities/NNS
and/CC
caveats/NNS
of/IN
gene/NN
expression/NN
profiling/VBG
in/IN
the/DT
context/NN
of/IN
mechanistic/JJ
and/CC
predictive/JJ
toxicology/NN
and/CC
have/VBP
addressed/VBN
the/DT
certainty/JJ
,/,
biological/JJ
relevance/NN
./.
====================
Therefore/RB
,/,
toxicogenomics/NNS
and/CC
proteomics/NNS
will/MD
certainly/RB
become/VBP
generally/RB
used/VBN
technologies/NNS
in/IN
the/DT
near/JJ
future/JJ
./.
====================
Health/RB
Risk/NN
Assessment/JJ
and/CC
Biomarkers/NNS
:/:
Biomarkers/NNS
will/MD
play/VB
an/DT
important/JJ
role/NN
in/IN
early/JJ
detection/NN
of/IN
environmentally/RB
induced/VBD
disease/NN
,/,
since/IN
routine/NN
surveillance/NN
programs/NNS
in/IN
both/DT
human/JJ
and/CC
animals/NNS
in/IN
suspected/JJ
environmentally/RB
hazardous/JJ
areas/NNS
could/MD
be/VB
instituted/VBN
./.
====================
Toxicogenomics/NNS
and/CC
proteomics/NNS
are/VBP
also/RB
providing/VBG
new/JJ
biomarkers/NNS
for/IN
====================
use/NN
in/IN
human/JJ
studies/NNS
./.
====================
It/PRP
is/VBZ
now/RB
possible/JJ
to/TO
envision/NN
schemes/VBZ
for/IN
integrating/VBG
the/DT
results/NNS
of/IN
molecular/JJ
epidemiological/JJ
investigations/NNS
into/IN
the/DT
general/JJ
toxicological/JJ
evaluations/NNS
of/IN
environmental/JJ
agents/NNS
./.
====================
These/DT
will/MD
allow/VB
intermediate/JJ
endpoints/NNS
to/TO
be/VB
used/VBN
for/IN
making/VBG
realistic/JJ
human/JJ
health/NN
assessments/NNS
and/CC
for/IN
elucidating/VBG
pathogenic/JJ
mechanisms/NNS
that/WDT
identify/VBP
targets/NNS
for/IN
intervention/NN
,/,
all/DT
with/IN
the/DT
goal/NN
of/IN
preventing/VBG
environmentally/RB
mediated/VBN
human/JJ
disease/NN
./.
====================
Also/RB
,/,
select/JJ
biomarker/NN
responses/NNS
that/DT
predict/VBP
the/DT
likelihood/JJ
of/IN
disease/NN
occurrence/NN
will/MD
find/VBP
application/NN
in/IN
the/DT
interpretation/NN
of/IN
individual/JJ
medical/JJ
diagnostic/JJ
tests/NNS
,/,
with/IN
the/DT
goal/NN
of/IN
improving/VBG
cancer/NN
detection/NN
and/CC
management/JJ
./.
====================
The/DT
objective/NN
is/VBZ
to/TO
determine/VB
whether/IN
gene/NN
,/,
protein/NN
or/CC
metabolite/NN
expression/NN
profiles/NNS
or/CC
’/NN
’/CD
signatures/NNS
”/CD
can/MD
serve/VB
as/IN
markers/NNS
to/TO
predict/VB
toxicity/NN
./.
====================
Current/JJ
efforts/NNS
are/VBP
underway/NN
to/TO
establish/VB
``/CD
best/JJS
choices/NNS
and/CC
practices/VBZ
”/CD
and/CC
perform/NN
proof-of/IN
principle/JJ
experiments/NNS
to/TO
phenotypically/RB
anchor/NN
altered/JJ
patterns/NNS
of/IN
expression/NN
to/TO
conventional/JJ
parameters/NNS
of/IN
toxicity/NN
./.
====================
These/DT
trials/NNS
are/VBP
more/RBR
closely/RB
define/VBP
the/DT
time/NN
and/CC
dose/NN
relationships/NNS
to/TO
express/VB
``/NN
signatures/NNS
''/CD
that/DT
develope/VBP
tools/NNS
of/IN
predictive/JJ
toxicology/NN
and/CC
elucidate/VB
common/JJ
mechanism/NN
of/IN
toxicity/NN
and/CC
drug/NN
action/NN
./.
====================
Early/JJ
detection/NN
of/IN
toxic/JJ
exposures/NNS
is/VBZ
a/DT
developing/VBG
art/VBP
,/,
but/CC
many/JJ
groups/NNS
have/VBP
already/RB
successfully/RB
classified/VBN
chemical/JJ
exposures/NNS
based/VBN
on/IN
profiling/VBG
of/IN
mRNA/NN
from/IN
treated/VBN
animals/NNS
(/(
Bartosiewicz/NN
et/FW
aL/FW
,/,
2001a/NN
,/,
b/LS
;/:
Hamadeh/NNP
et/FW
al./FW
,/,
2002a/NN
,/,
b/LS
,/,
c/NN
)/)
./.
====================
This/DT
kind/NN
of/IN
information/NN
might/MD
be/VB
useful/JJ
for/IN
risk/NN
assessment/NN
in/IN
that/DT
significant/JJ
changes/NNS
in/IN
expression/NN
in/IN
a/DT
small/JJ
set/NN
of/IN
highly/RB
discriminatory/JJ
genes/NNS
can/MD
together/RB
act/VBP
as/IN
a/DT
biomarker/NN
of/IN
toxic/JJ
mechanisms/NNS
or/CC
endpoints/NNS
./.
====================
Toxicoirrfoimatics/NNS
:/:
There/EX
is/VBZ
more/RBR
specified/VBN
fields/NNS
such/JJ
astoxicoinformatics/NNS
./.
====================
Toxicoinformatics/NNS
is/VBZ
the/DT
important/JJ
factor/NN
of/IN
toxicogenomics/NNS
field/NN
./.
====================
Toxicoinformatics/NNS
is/VBZ
essential/JJ
computational/JJ
tools/NNS
for/IN
the/DT
analysis/NN
of/IN
time-/NN
and/CC
dose­/JJ
dependent/JJ
changes/NNS
in/IN
patterns/NNS
of/IN
toxicant-induced/JJ
gene/NN
expression/NN
./.
====================
Development/NN
of/IN
these/DT
capabilities/NNS
will/MD
require/VB
a/DT
database/NN
that/DT
complies/VBZ
high/JJ
quality/NN
data/NNS
from/IN
diverse/JJ
sources/NNS
involving/VBG
different/JJ
gene/NN
expression/NN
platforms/VBZ
,/,
assay/NN
methods/NNS
,/,
validation/NN
results/NNS
and/CC
diverse/JJ
drugs/NNS
,/,
chemicals/NNS
or/CC
environmental/JJ
agents/NNS
./.
====================
Complete/JJ
analysis/NN
will/MD
require/VB
linkage/NN
between/IN
and/CC
among/IN
additional/JJ
databases/NNS
that/IN
provide/VBP
most/JJS
current/JJ
sequence/NN
identity/NN
can/MD
annotate/VB
gene/NN
identify/VBP
and/CC
function/NN
,/,
chemical/JJ
structure/NN
,/,
toxicity/NN
,/,
pathology/NN
,/,
pharmacokinetics/biodistribution/NN
,/,
and/CC
genotoxicity/NN
(/(
Mattes/NNS
et/FW
al./FW
,/,
2004/CD
;/:
Mattingly/RB
et/FW
al./FW
,/,
2004/CD
;/:
Olden/RB
etal./FW
,/,
2004/CD
;/:
Tong/JJ
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
International/JJ
Harmonization/NN
and/CC
QA/QC/NN
:/:
To/TO
promote/VB
the/DT
further/JJ
development/NN
and/CC
application/NN
of/IN
the/DT
``/NN
omic/JJ
''/NNP
technologies/NNS
to/TO
toxicology/NN
and/CC
environmental/JJ
health/NN
risk/NN
assessment/NN
,/,
recently/RB
,/,
on/IN
Oct/NN
12-13/NN
,/,
Toxicogenomics/NNS
International/JJ
Forum/NNP
(/(
2004/CD
)/)
was/VBD
held/RB
,/,
and/CC
continuosly/RB
,/,
OECD/IPCS/NNP
organized/VBN
a/DT
special/JJ
workshop/NN
for/IN
toxicogenomics/NNS
focusing/VBG
eco-toxicogenomics/NNS
at/IN
Kyoto/JJ
,/,
Japan/NNP
on/IN
Oct/NN
13-15/CD
,/,
2004/CD
./.
====================
In/IN
this/DT
OECD/IPCS/NN
workshop/NN
(/(
2004/CD
)/)
,/,
4/CD
group/NN
sessions/NNS
open/JJ
to/TO
discuss/VB
the/DT
problems/NNS
and/CC
future/JJ
plan/NN
of/IN
toxicogenomics/NNS
,/,
especially/RB
focused/VBN
on/IN
eco-/JJ
toxicogenomics/NNS
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
One/CD
is/VBZ
biological/JJ
breakout/NN
group/NN
and/CC
they/PRP
summarized/VBD
that/DT
toxicogenomic/JJ
technologies/NNS
have/VBP
unique/JJ
opportunities/NNS
to/TO
address/VB
ecological/JJ
and/CC
human/JJ
health/NN
concerns/VBZ
,/,
such/JJ
as/IN
;/:
i/LS
)/)
offering/VBG
possibilities/VBZ
to/TO
reduce/VB
,/,
refine/VBP
and/CC
replace/VBP
====================
costly/RB
animal/NN
intensive/JJ
methods/NNS
for/IN
chemical/JJ
screening/NN
and/CC
testing/NN
,/,
ii/LS
)/)
understanding/VBG
how/WRB
and/CC
why/WRB
species/NNS
and/CC
subgroups/NNS
differ/VBP
in/IN
sensitivity/NN
and/CC
response/NN
to/TO
chemical/JJ
stress/NN
,/,
and/CC
create/VBP
a/DT
stronger/JJR
scientific/JJ
foundation/NN
for/IN
the/DT
safety/NN
factors/NNS
./.
====================
This/DT
will/MD
allow/VB
effective/JJ
policies/NNS
to/TO
be/VB
developed/VBN
in/IN
order/NN
to/TO
protect/VB
endangered/JJ
and/CC
importance/NN
species/NNS
,/,
iii/LS
)/)
assessing/VBG
the/DT
effects/NNS
of/IN
chemical/JJ
mixtures/NNS
and/CC
combination/NN
of/IN
stressors/NNS
./.
====================
Previously/RB
,/,
appropriate/JJ
methods/NNS
have/VBP
been/VBN
lacking/VBG
,/,
iv/LS
)/)
reduced/VBD
uncertainty/JJ
in/IN
assessment/NN
of/IN
ecological/JJ
conditions/NNS
./.
====================
These/DT
will/MD
allow/VB
effective/JJ
policies/NNS
to/TO
be/VB
developed/VBN
to/TO
protect/VB
endangered/JJ
and/CC
important/JJ
species/NNS
./.
====================
For/IN
these/DT
reasons/NNS
,/,
it/PRP
is/VBZ
important/JJ
that/IN
these/DT
new/JJ
tools/NNS
are/VBP
evaluated/VBN
and/CC
implemented/VBD
for/IN
chemical/JJ
risk/NN
assessment/NN
./.
====================
In/IN
the/DT
technical/JJ
group/NN
,/,
several/JJ
useful/JJ
technical/JJ
tools/NNS
such/JJ
as/IN
global/JJ
oligo/JJ
array/NN
,/,
global/JJ
cDNA/NN
array/NN
,/,
targeted/VBN
oligo/JJ
array/NN
,/,
targeted/VBN
cDNA/NN
array/NN
,/,
Q-PCR/NN
and/CC
SAGE/NN
for/IN
transcriptomics/NNS
,/,
and/CC
2D-MALDI/CD
,/,
2D-MS/MS/NNP
,/,
Ciphergen-IVALDI/NNP
,/,
Protein/NN
arrays/NNS
,/,
LC-MS/MS/NN
,/,
ICAT-MALDI/NN
,/,
ICAT-MS/MS/NN
and/CC
ELISA/NN
for/IN
proteomics/NNS
,/,
and/CC
NMR/NN
,/,
targeted/VBN
MS-based/JJ
,/,
LC-electrochemical/JJ
for/IN
metabolomics/NNS
were/VBD
discussed/VBN
./.
====================
The/DT
regulatory/JJ
usefulness/NN
of/IN
toxicogenomic/JJ
tools/NNS
is/VBZ
very/RB
important/JJ
(/(
Frueh/NN
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
In/IN
this/DT
respect/NN
,/,
in/IN
the/DT
regulatory/JJ
group/NN
,/,
expected/VBN
outcomes/NNS
are/VBP
a/DT
road/JJ
map/VBP
for/IN
development/NN
,/,
validation/NN
and/CC
regulatory/JJ
use/NN
of/IN
genomic­/JJ
based/VBN
tools/NNS
,/,
proposals/VBZ
for/IN
further/JJ
activities/NNS
related/JJ
to/TO
the/DT
use/NN
of/IN
genomic-based/VBN
methods/NNS
in/IN
chemical/JJ
assessment/NN
and/CC
promotion/NN
of/IN
related/JJ
research/NN
to/TO
be/VB
undertaken/VBN
within/IN
the/DT
OECD/NN
Environment/JJ
,/,
Health/RB
and/CC
Safety/NN
Programme/NNP
,/,
and/CC
proposals/NNS
for/IN
mechanism/NN
of/IN
international/JJ
co-ordination/NN
for/IN
the/DT
development/NN
,/,
validation/NN
and/CC
regulatory/JJ
use/NN
of/IN
genome-based/VBN
tools/NNS
./.
====================
The/DT
bioinformatics/NNS
group/NN
adopted/JJ
general/JJ
recommendations/NNS
such/JJ
as/IN
1/LS
)/)
stable/JJ
funding/VBG
and/CC
adequate/JJ
funding/VBG
must/MD
be/VB
provided/VBN
to/TO
a/DT
national/JJ
and/CC
internationals/VBZ
level/NN
for/IN
standardization/NN
initiatives/VBZ
,/,
database/RB
and/CC
tool/RB
development/NN
and/CC
long-term/JJ
maintenance/NN
,/,
2/CD
)/)
provide/VBP
training/VBG
in/IN
data/NNS
requirements/VBZ
and/CC
bioinformatics/NNS
issues/VBZ
relating/VBG
to/TO
ecotoxicogenomics/DT
for/IN
risk/NN
assessors/NNS
,/,
3/LS
)/)
governments/VBZ
should/MD
promote/VB
synergy/NN
between/IN
the/DT
toxicology/NN
and/CC
ecotoxicology/RB
communities/VBZ
,/,
including/VBG
a/DT
trialogue/JJ
between/IN
scientists/NNS
,/,
regulators/NNS
and/CC
bioinformaticians/NNS
on/IN
an/DT
international/JJ
scale/JJ
,/,
4/CD
)/)
in/IN
the/DT
broader/RBR
context/RB
of/IN
ecotoxicogenomics/NNS
studies/NNS
,/,
initial/JJ
efforts/NNS
should/MD
be/VB
centered/JJ
on/IN
a/DT
few/JJ
species/NNS
representative/JJ
of/IN
the/DT
ecological/JJ
complexity/NN
,/,
and/CC
5/CD
)/)
establish/VBP
a/DT
task/JJ
force/working/VBG
group/NN
to/TO
implement/JJ
these/DT
recommendations/NNS
and/CC
coordinate/JJ
future/JJ
actions/NNS
./.
====================
The/DT
ultimate/JJ
promise/JJ
of/IN
toxicogenomics/NNS
lies/VBZ
in/IN
its/PRP$
potential/JJ
ability/NN
;/:
(/(
i/LS
)/)
to/TO
identify/VB
sources/NNS
of/IN
interindividual/JJ
variability/NN
in/IN
response/NN
to/TO
drugs/NNS
and/CC
environmental/JJ
xenobiotics/NNS
,/,
both/CC
in/FW
terms/NNS
of/IN
efficacy/NN
and/CC
toxicity/NN
;/:
This/DT
====================
area/NN
of/IN
research/NN
requires/VBZ
genetics/NNS
knowledge/NN
regarding/VBG
individual/JJ
variation/NN
which/WDT
determines/VBZ
person/NN
's/POS
responses/NNS
to/TO
drugs/NNS
and/CC
xenobiotics/NNS
;/:
(/(
ii/LS
)/)
to/TO
provide/VB
a/DT
database/NN
for/IN
the/DT
development/NN
of/IN
high-throughput/JJ
and/CC
low-cost/JJ
platforms/NNS
for/IN
screening/VBG
substances/NNS
for/IN
toxicity/NN
;/:
and/CC
(/(
iii/LS
)/)
to/TO
improve/VB
the/DT
process/NN
of/IN
discovering/VBG
new/JJ
targets/NNS
for/IN
drug/NN
action/NN
./.
====================
However/RB
,/,
the/DT
high/JJ
degree/NN
of/IN
QA/QC/NN
on/IN
microarray/NN
chips/NNS
to/TO
produce/VB
more/RBR
reliable/JJ
data/NNS
will/MD
be/VB
remained/VBN
to/TO
be/VB
solve/JJ
at/IN
present/JJ
./.
====================
As/IN
every/RB
human/JJ
being/VBG
on/IN
the/DT
earth/JJ
are/VBP
unique/JJ
in/IN
their/PRP$
genetic/JJ
make/VBP
up/IN
,/,
there/EX
are/VBP
huge/JJ
variations/NNS
in/IN
responses/NNS
against/IN
outer/JJ
environmental/JJ
factors/NNS
and/CC
also/RB
in/IN
susceptibility/NN
to/TO
a/DT
disease/NN
./.
====================
As/IN
the/DT
medical/JJ
research/NN
is/VBZ
getting/VBG
into/IN
the/DT
arena/NNS
of/IN
personalized/VBN
medicine/NN
which/WDT
applies/VBZ
individual/JJ
's/POS
genetic/JJ
information/NN
in/IN
disease/NN
treatment/NN
and/CC
selection/NN
of/IN
drugs/NNS
,/,
toxicogenomic/JJ
research/NN
also/RB
have/VBP
to/TO
look/VB
into/IN
the/DT
individual/JJ
genetic/JJ
differences/NNS
./.
====================
A/DT
genetic/JJ
variation/NN
which/WDT
is/VBZ
involved/VBN
in/IN
metabolism/NN
of/IN
toxicants/NNS
and/CC
chemicals/NNS
can/MD
answer/VB
the/DT
questions/NNS
of/IN
why/WRB
some/DT
people/JJ
react/VBP
more/RBR
sensitively/RB
to/TO
same/JJ
environments/NNS
than/IN
others/NNS
./.
====================
Careful/JJ
cataloging/VBG
of/IN
association/NN
between/IN
genetic/JJ
background/NN
and/CC
responses/NNS
to/TO
toxic/JJ
substances/NNS
will/MD
serve/VB
as/IN
a/DT
powerful/JJ
tool/NN
to/TO
understand/VB
toxicological/JJ
phenomenon/NN
./.
====================
This/DT
way/NN
,/,
one/CD
can/MD
possibly/RB
assess/VB
each/DT
individual/JJ
's/POS
risks/NNS
in/IN
a/DT
given/VBN
environment/NN
and/CC
design/NN
a/DT
plan/JJ
to/TO
avoid/VB
any/DT
toxic/JJ
effects/NNS
./.
====================
Consequently/RB
,/,
toxicogenomics/NNS
will/MD
be/VB
a/DT
great/JJ
promising/VBG
next/RB
generation/NN
technology/NN
(/(
Waring/VBG
and/CC
Halbert/NN
,/,
2002/CD
)/)
in/IN
the/DT
fields/NNS
of/IN
health/NN
risk/NN
assessment/NN
,/,
drug/NN
safety/NN
,/,
food/NN
safety/NN
and/CC
forensic/JJ
toxicology/NN
etc/JJ
./.
====================
Additionally/RB
,/,
there/EX
will/MD
a/DT
new/JJ
paradigm/NN
that/DT
is/VBZ
systems/NNS
biology/NN
./.
====================
The/DT
confluence/NN
of/IN
omics/NNS
,/,
bioinformatics/NNS
,/,
mechanistic/JJ
studies/NNS
at/IN
the/DT
molecular/JJ
level/NN
,/,
and/CC
computational/JJ
biology/NN
has/VBZ
yielded/VBD
a/DT
new/JJ
discipline/JJ
called/VBN
systems/NNS
biology/NN
(/(
Oltvai/NNP
and/CC
Barabasi/NN
,/,
2002/CD
)/)
./.
''/CD
====================
Systems/NNS
biology/NN
is/VBZ
a/DT
new/JJ
field/NN
of/IN
biology/NN
that/DT
aims/VBZ
to/TO
develop/VB
a/DT
system-level/JJ
understanding/NN
of/IN
biological/JJ
systems/NNS
(/(
Kitano/NN
,/,
2002/CD
)/)
./.
====================
It/PRP
requires/VBZ
collective/JJ
efforts/NNS
from/IN
multiple/JJ
research/NN
areas/NNS
,/,
such/JJ
as/IN
molecular/JJ
biology/NN
(/(
genomics/NNS
)/)
,/,
high-precision/JJ
measurement/NN
,/,
computer/NN
science/NN
,/,
control/NN
theory/JJ
and/CC
other/JJ
scientific/JJ
and/CC
engineering/VBG
fields/NNS
./.
====================
